Why in news?
Scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) in Bengaluru, in collaboration with the Indian Institute of Science, have developed an innovative imaging platform called Cleavable Light‑Erased Antibody Reporter (CLEAR). The technique allows researchers to visualise dozens of different proteins within the same biological sample using a single fluorescent tag that can be erased and re‑used. This breakthrough promises to transform biomedical research and precision medicine.
Background
Mapping the spatial distribution of proteins in cells and tissues provides vital clues about how diseases progress. Traditional immunofluorescence methods label each protein with a distinct dye, limiting the number of markers that can be imaged because different dyes emit overlapping light. CLEAR overcomes this barrier by attaching a light‑cleavable “eraser” to antibodies. Once a set of proteins is imaged, the fluorescent tag can be removed with a brief burst of ultraviolet light, allowing the same dye to be used again on the next set of proteins. This cycle of labelling, imaging and erasing can be repeated many times, generating a high‑plex map of proteins with minimal sample damage.
How CLEAR works
- Light‑cleavable probes: Antibodies are linked to a fluorophore through a special chemical group that breaks when exposed to 365 nm UV light. After imaging the sample, the fluorescent tag is cleaved off, leaving the proteins unlabelled and ready for the next cycle.
- Single dye strategy: Because the same fluorophore can be reused, CLEAR avoids spectral overlap and simplifies microscope design. Researchers can map tens of proteins using standard equipment.
- High spatial resolution: The method preserves the fine structure of cells and tissues, enabling scientists to identify where proteins are located within sub‑cellular compartments.
- Speed and compatibility: Labelling and erasing cycles take only a few minutes, and the technique works on a variety of specimens, from single cells to complex tissue slices. It is gentle enough for delicate samples and may be adapted for live‑cell imaging in the future.
Potential applications
- Early disease detection: By mapping multiple proteins associated with cancer or neurodegenerative diseases, scientists can identify disease signatures at an early stage and track how they change over time.
- Precision medicine: CLEAR can help clinicians characterise tumours and tailor treatments based on the unique protein profile of each patient’s cells.
- Fundamental research: Understanding how proteins interact within cells is essential for unravelling the mechanisms of development, immunity and ageing. CLEAR provides a powerful tool for such studies.
Conclusion
The CLEAR platform demonstrates how a simple chemical trick can expand the reach of fluorescence imaging. By enabling repeated cycles of labelling and erasing, it offers researchers a cost‑effective and gentle method to visualise many proteins in situ. As the technique matures, it could usher in new possibilities for diagnostics and personalised therapies.